Research programme: neuroimmunophilin ligands - Astellas
Alternative Names: FK 1706Latest Information Update: 16 Jul 2016
At a glance
- Originator Astellas Pharma
- Class Neuroprotectants
- Mechanism of Action Immunophilin modulators; Interleukin 2 receptor antagonists; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neurological-disorders in Japan (PO)
- 21 Oct 2005 Preclinical trials in Neurological disorders in Japan (unspecified route)